The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities
Open Access
- 7 June 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 7, 99
Abstract
Tet methylcytosine dioxygenase 2 (TET2) is a tumor suppressor gene that is inactivated in a wide range of hematological cancers. TET2 enzymatic activity converts 5-methylcytosine (5-mC) into 5-hydroxymethylcytosine (5-hmC), an essential step in DNA demethylation. Human TET2 is highly expressed in pluripotent cells and down-regulated in differentiated cells: however, transcriptional regulation of the human TET2 gene has not been investigated in detail. Here we define three promoters within a 2.5 kb region located ∼ 87 kb upstream of the first TET2 coding exon. The three promoters, designated as Pro1, Pro2, and Pro3, generate three alternative first exons, and their presence in TET2 mRNAs varies with cell type and developmental stage. In general, all three TET2 transcripts are more highly expressed in human tissues rich in hematopoietic stem cells, such as spleen and bone marrow, compared to other tissues, such as brain and kidney. Transcripts from Pro2 are expressed by a broad range of tissues and at a significantly higher level than Pro1 or Pro3 transcripts. Pro3 transcripts were highly expressed by embryoid bodies generated from the H9 ES cell line, and the major Pro3 transcript is an alternatively spliced mRNA isoform that produces a truncated TET2 protein lacking the catalytic domain. Our study demonstrates distinct tissue-specific mechanisms of TET2 transcriptional regulation during early pluripotent states and in differentiated cell types.Keywords
Funding Information
- Frederick National Laboratory for Cancer Research
This publication has 35 references indexed in Scilit:
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsNature, 2018
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancerNature Genetics, 2014
- NANOG-dependent function of TET1 and TET2 in establishment of pluripotencyNature, 2013
- Combined Deficiency of Tet1 and Tet2 Causes Epigenetic Abnormalities but Is Compatible with Postnatal DevelopmentDevelopmental Cell, 2013
- Landscape of transcription in human cellsNature, 2012
- Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2Nature, 2012
- Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylationNucleic Acids Research, 2012
- Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African AmericansPLOS Genetics, 2011
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyNature Genetics, 2009
- VISTA: computational tools for comparative genomicsNucleic Acids Research, 2004